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Abstract	  
The	  CTLA-­‐4	  checkpoint	  regulates	  the	  activation	  of	  T	  cells.	  	  Individuals	  with	  heterozygous	  
mutations	   in	   CTLA-­‐4	   have	   a	   complex	   phenotype	   typically	   characterized	   by	   antibody	  
deficiency	  alongside	  variable	  autoimmunity.	  Despite	  severe	  disease	  in	  some	  individuals,	  
others	  remain	  largely	  unaffected	  with	  reasons	  for	  this	  variation	  unknown.	  We	  studied	  a	  
large	  family	  carrying	  a	  single	  point	  mutation	  in	  CTLA-­‐4	  leading	  to	  an	  amino	  acid	  change	  
R75W	  and	  compared	  both	  unaffected	  with	  affected	  individuals.	  We	  measured	  a	  variety	  
of	  features	  pertaining	  to	  T	  cell	  and	  CTLA-­‐4	  biology	  and	  observed	  that	  at	  the	  cellular	  level	  
there	   was	   complete	   penetrance	   of	   CTLA-­‐4	   mutations.	   Accordingly,	   unaffected	  
individuals	  were	   indistinguishable	   from	   those	  with	  disease	   in	   terms	  of	   level	  of	  CTLA-­‐4	  
expression,	   percentage	   of	   Treg,	   upregulation	   of	   CTLA-­‐4	   upon	   stimulation	   and	  
proliferation	  of	  CD4	  T	  cells.	  We	  conclude	  that	  the	  wide	  variation	  in	  disease	  phenotype	  is	  






CTLA-­‐4;	  CD28;	  immunodeficiency;	  autoimmunity;	  mutation;	  regulatory	  T	  cells;	   	  
	  	   3	  
	  
1.	  Introduction	  
The	   ability	   to	   regulate	   the	   activity	   of	   T	   lymphocytes	   is	   central	   to	   immune	   health	   and	  
dysregulation	  of	  this	  process	  leads	  to	  a	  wide	  array	  of	  immune	  pathologies	  affecting	  both	  
T	  and	  B	  cells.	  In	  particular,	  the	  decision	  to	  activate	  T	  cells	  is	  tightly	  regulated	  since	  the	  T	  
cell	   repertoire	   contains	   significant	   reactivity	   to	   self-­‐antigens[1]	   resulting	   from	  
incomplete	  negative	  selection	  in	  the	  thymus[2,	  3].	  The	  peripheral	  tolerance	  mechanisms	  
that	  mitigate	  this	  self-­‐reactivity	  include	  the	  presence	  of	  specialized	  regulatory	  T	  cells[4]	  
and	   the	  expression	  of	  proteins	   such	  as	  CTLA-­‐4[5].	   	   The	   fact	   that	  CTLA-­‐4	   is	   abundantly	  
expressed	  by	  Treg	  and	   is	   required	   for	   their	   efficient	   function	  highlights	   the	   significant	  
intersection	   of	   these	   pathways[6].	   Consequently,	   defects	   in	   Treg	   development[7,	   8],	  
CTLA-­‐4	   expression[9]	   and	   pathways	   affecting	   CTLA-­‐4	   trafficking[10]	   all	   result	   in	  
significant	   immune	   dysregulation	   and	   autoimmunity	   affecting	   a	   wide	   range	   of	   target	  
organs.	  Recently,	  heterozygous	  mutations	   in	  CTLA-­‐4	  have	  been	  reported	   in	   individuals	  
suffering	   from	  a	   form	  of	   common	  variable	   immunodeficiency	   (CVID)[11,	   12]	  however,	  
this	  disease	  is	  incompletely	  penetrant	  with	  ~70%	  of	  individuals	  carrying	  mutations	  being	  
overtly	   affected.	   This	   raises	   the	   question	   of	   what	   additional	   factors	   affect	   disease	  
manifestation?	  
	  
CTLA-­‐4	   is	  a	  negative	  regulator	  that	  opposes	  a	  related	  receptor	  on	  T	  cells,	  CD28,	  which	  
serves	  to	  reinforce	  or	  “co-­‐stimulate”	  T	  cell	  activation.	  CD28	  and	  CTLA-­‐4	  also	  share	  the	  
same	  ligands,	  CD80	  and	  CD86,	  expressed	  by	  antigen	  presenting	  cells	  and	  upregulation	  of	  
these	   ligands	   in	   response	   to	   inflammatory	   signals	   during	   infection	   increases	   CD28	  
costimulation[13].	  In	  contrast,	  binding	  of	  these	  same	  ligands	  by	  CTLA-­‐4	  down-­‐regulates	  
their	  expression	  thereby	  regulating	  T	  cell	  activation[14-­‐16].	  Ligand	  downregulation	  can	  
be	  mediated	  by	   transendocytosis,	  whereby	  CTLA-­‐4	  physically	   removes	   its	   ligands	   from	  
antigen	  presenting	  cells	  and	  degrades	  them	  in	  lysosomes[17].	  In	  line	  with	  this	  concept,	  
defects	   in	   the	  LPS-­‐responsive	  and	  beige-­‐like	  anchor	   (LRBA)	  gene,	  which	  affects	  CTLA-­‐4	  
trafficking	  and	  degradation,	  result	  in	  low	  levels	  of	  CTLA-­‐4	  expression	  and	  defective	  Treg	  
function[10,	   18].	   The	   fact	   that	   LRBA	   deficiency	   largely	   phenocopies	   CTLA-­‐4	   deficiency	  
supports	  a	  general	  concept	  that	  the	  amount	  and	  correct	  trafficking	  of	  CTLA-­‐4	  is	  critical	  
to	  maintaining	  its	  function	  in	  self-­‐	  tolerance.	  
In	   addition	   to	   directly	   affecting	   Treg	   function,	   the	   CD28/CTLA-­‐4	   pathway	   also	   plays	   a	  
significant	   role	   in	   maintaining	   Treg	   homeostasis.	   Accordingly,	   both	   CD28	   and	   ligand-­‐
deficient	  mice	   have	   low	  numbers	   of	   Treg[19],	  whereas	   deficiency	   of	   CTLA-­‐4	   increases	  
Treg	  numbers	   [20].	   The	   latter	   effect	   is	   due	   to	   the	   fact	   that	   in	   the	   absence	  of	   CTLA-­‐4,	  
CD28	   has	   increased	   access	   to	   its	   ligands	   thereby	   promoting	   Treg	   proliferation	   and	  
survival.	  Somewhat	  surprisingly,	  LRBA	  deficient	  individuals	  (who	  have	  low	  CTLA-­‐4)	  have	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been	   reported	   to	   have	   lower	   numbers	   of	   Treg[21],	   although	   this	   was	   not	   seen	   in	  
another	   study	   [22].	  Nonetheless,	   it	   is	   clear	   that	  a	  delicate	  balance	  between	  CD28	  and	  
CTLA-­‐4	  biology	  plays	  a	  significant	  role	  in	  both	  Treg	  homeostasis	  and	  function,	  which	  is	  as	  
yet	  poorly	  understood	  in	  humans.	  To	  better	  understand	  these	  aspects	  of	  CTLA-­‐4	  biology	  
we	  took	  advantage	  of	  a	  large	  family	  carrying	  a	  heterozygous	  missense	  (R75W)	  mutation	  
in	   CTLA-­‐4	   and	   looked	   for	   differences	   between	   affected	   and	   unaffected	   individuals	  
carrying	   the	   same	   CTLA-­‐4	  mutation.	   The	   data	   presented	   here	   revealed	   no	   detectable	  
differences	   in	   CTLA-­‐4	   expression,	   response	   to	   stimulation	   or	   Treg	   homeostasis,	   when	  
comparing	   affected	   and	   unaffected	   individuals.	   Together	   this	   suggests	   that	   the	  
difference	  in	  clinical	  status	  between	  affected	  and	  unaffected	  mutation	  carriers	  does	  not	  
lie	  within	  the	  CD28/CTLA-­‐4	  pathway	  itself.	  	  
	  
2.	  Materials	  and	  Methods	  
	  
2.1	  Clinical	  phenotype:	  
In	  absence	  of	  a	  CTLA-­‐4	  specific	  disease	  stratification	  system	  the	  study	  team	  decided	  to	  
clinically	   stratify	   patients	   according	   to	   their	   symptoms:	   asymptomatic	   (0	   symptoms),	  
mild	   to	   moderate	   (1-­‐5	   symptoms)	   and	   severe	   (>5	   symptoms)	   affected	   as	   detailed	   in	  
table	  1.	  All	  study	  participants	  were	  evaluated	  in	  a	  personal	   interview	  and	  a	  systematic	  
chart	  review	  was	  performed	  in	  patients	  with	  clinical	  manifestations,	  adapted	  from	  [12].	  
In	   addition,	   the	   attending	   physician	   was	   contacted	   in	   order	   to	   complement	   missing	  
details	  when	  appropriate.	  
	  
2.2	   Sequencing:	   For	   Whole	   Exome	   Sequencing	   (WES),	   extracted	   genomic	   DNA	   was	  
randomly	  fragmented,	  amplified	  by	   ligation-­‐mediated	  polymerase	  chain	  reaction	  (PCR)	  
and	   captured	   and	   sequenced	   according	   to	   the	   protocol	   of	   the	   manufacturer	   as	  
described	   previously	   [23].	   	   Sequences	   were	   generated	   and	   aligned	   to	   the	   human	  
genome	   reference	   (UCSC	   hg	   19	   version;	   build	   37.1)	   using	   the	   SOAP	   aligner	   software	  
(soap	  v.2.21).	  Duplicated	  reads	  were	  filtered	  out	  and	  only	  uniquely	  mapped	  reads	  were	  
kept	   for	   subsequent	   analyses.	   The	   SOAPsnp	   software	   (v.1.03)	  was	   subsequently	   used	  
with	   default	   parameters	   to	   assemble	   the	   consensus	   sequence	   and	   call	   genotypes	   in	  
target	  regions	  [23].	  Low-­‐quality	  single	  nucleotide	  polymorphisms	  (SNP)	  that	  met	  one	  of	  
the	   four	   following	   criteria	   were	   filtered	   out:	   a	   genotype	   quality	   of	   less	   than	   20;	   a	  
sequencing	   depth	   of	   less	   than	   4;	   an	   estimated	   copy	   number	   of	   more	   than	   2	   and	   a	  
distance	   from	   the	   adjacent	   SNPs	   of	   less	   than	   5	   bp.	   Small	   insertions/deletions	   (Indels)	  
were	   detected	   using	   the	  Unified	  Genotype	   tool	   from	  GATK	   (v.1.0.4705)	   following	   the	  
alignment	  of	  quality	  reads	  to	  the	  human	  reference	  genome	  using	  BWA	  (v.0.5.9-­‐r16).	  As	  
previously	  described,	   sequencing	  data	  analysis	  was	  performed	   focusing	  particularly	  on	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known	  PID	  genes	  as	  well	  as	  their	  interacting	  genetic	  partners	  [23].	  
	  	  
2.3	  PBMC	  isolation	  
Patient	  samples	  were	  submitted	  for	  the	  purpose	  of	  diagnostic	  evaluation	  and	  processed	  
under	   institutional	   approval	   for	   the	   investigation	   of	   immunodeficiency.	   Blood	   was	  
diluted	   at	   1/1	   with	   phosphate-­‐buffered	   saline,	   layered	   on	   Ficoll-­‐Paque	   PLUS	   (GE	  
Healthcare),	   and	   centrifuged	   at	   1060g	   for	   25	  minutes.	   Peripheral	   blood	  mononuclear	  
cells	   (PBMCs)	   were	   resuspended	   in	   phosphate-­‐buffered	   saline	   containing	   2	   mM	  
EDTA/0.5%	  bovine	  serum	  albumin	  for	  T-­‐cell	  purification	  using	  a	  CD4+	  T-­‐cell	  enrichment	  
kit	  (StemCell).	  	  
	  
2.4	  Flow	  cytometry:	  
For	  surface	  staining,	  cells	  were	  incubated	  with	  CD25	  BV605	  (clone	  2A3;	  BD),	  CD4	  Alexa	  
Fluor	  700	  (clone	  RPA-­‐T4;	  BD),	  CD45RA	  PerCP–Cy5.5	  (clone	  HI100;	  eBioscience)	  at	  4°C	  for	  
30	   minutes.	   For	   analysis	   of	   total	   CTLA-­‐4	   and	   Foxp3	   expression,	   cells	   were	   fixed	   and	  
permeabilized	   with	   Foxp3	   staining	   buffer	   (eBioscience)	   and	   incubated	   with	   Foxp3	  
allophycocyanin	   (clone	   236A-­‐E7;	   eBioscience)	   and	   CTLA-­‐4	   phycoerythrin	   (clone	   BNI3;	  
BD).	  Cells	  were	  acquired	  on	  a	  BD	  LSRII	   cytometer	  and	   the	  data	  analyzed	  using	  FlowJo	  
software	   (TreeStar).	   In	   some	   experiments	   relative	   expression	   of	   CTLA-­‐4	   or	   CD25	   was	  
calculated	  based	  on:	  	  level	  of	  expression	  (MFI)	  in	  memory	  Treg	  (CD45RA-­‐	  Foxp3+)/	  level	  
of	  expression	  (MFI)	  in	  naïve	  conventional	  CD4	  cells	  (CD4+CD45RA+	  Foxp3-­‐)	  
	  
2.5	  T-­‐cell	  stimulation	  
CD4	  T	  cells	  were	  resuspended	  at	  1	  ×	  106/mL	  in	  RPMI	  1640	  with	  10%	  fetal	  bovine	  serum,	  
2	   mM	   l-­‐glutamine,	   1%	   penicillin,	   and	   1%	   streptomycin.	   96,000	   Tells	   were	   stimulated	  
with	  0.5µg/ml	  anti-­‐CD3	  plus	  72,000	  CHO-­‐cells	  expressing	  the	  CD80	  ligand	  as	  previously	  
described[24]	   .	   Cells	   were	   cultured	   in	   a	   96-­‐well	   round-­‐bottomed	   plate	   at	   37°C,	   95%	  





3.1	  Mutation	  identification	  and	  Clinical	  phenotype:	  	  
The detection of hypogammaglobulinemia in the context of recurrent respiratory and 
gastrointestinal infections in the son (V.1) of our index patient (IV.2) and 
hypogammaglobulinemia in her mother (III.2) resulted	   in	   a	   whole	   exome	   sequencing	  
approach	   identifying	   a	   previously	   described	   mutation	   in	   CTLA4	   (R75W)	   in	   all	   three	  
patients.	   Sanger	   sequencing	   confirmed	   this	   finding	   and	   an	   extensive	   family	   screening	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over	  four	  generations	  revealed	  a	  total	  of	  15	  mutation	  carriers	  (Figure	  1).	  The	  spectrum	  
and	   the	   severity	   of	   clinical	  manifestations	   were	   highly	   variable	   between	   the	   affected	  
individuals	   (Table	   1).	   Mild	   and	   variable	   skin	   disorders	   and	   recurrent	   non-­‐infectious	  
diarrhea/enteropathy	   were	   the	   most	   common	   clinical	   findings	   (60	   and	   53.3%	  
respectively).	   Dyslipidemia	   requiring	   pharmacologic	   intervention	   was	   frequently	  
reported	  (53.3%)	  and	  restricted	  to	  adult	  patients.	  Infectious	  manifestations	  ranged	  from	  
recurrent	   upper	   and	   lower	   respiratory	   tract	   infections	   (20%),	   recurrent	   salmonellosis	  
(20%),	   enterovirus	   (13.3%,	   poliomyelitis),	   persistent	   cutaneous	   papillomas	   (6.7%),	  
recurrent	   vaginal	   candidiasis	   (6.7%)	   and	   post-­‐infectious	   complications	   such	   as	   post-­‐
streptococcal	   nephritis	   (13.3%).	   Four	   patients	   (26.6%)	   showed	   neurologic	   symptoms	  
consisting	   mainly	   of	   progressive	   memory	   loss,	   however	   one	   patient	   suffered	   from	   a	  
severe	   developmental	   delay	   and	   seizures	   classified	   as	   West	   syndrome.	  
Lymphoproliferation	   (splenomegaly	   and/or	   lymphadenopathy)	   was	   seen	   in	   20%	   of	  
patients.	  Autoimmune	  manifestations	  (thyroiditis,	  arthritis	  and	  gastritis)	  were	  reported	  
in	   three	   patients,	   however	   none	   of	   the	   individuals	   had	   autoimmune	   cytopenias.	   One	  
patient	   was	   successfully	   treated	   for	   breast	   cancer	   and	   one	   patient	   was	   recently	  
diagnosed	   with	   a	   massive	   mesenteric	   panniculitis.	   Three	   patients	   reported	   non-­‐
infectious	  liver	  disease	  requiring	  organ	  transplantation	  in	  one	  patient	  who	  subsequently	  
developed	   post-­‐transplant	   lymphoproliferative	   disease.	   None	   of	   the	   patients	   suffered	  
from	  recurrent	  or	  invasive	  CMV,	  EBV	  or	  VZV	  infection.	  
Three	  patients	  in	  our	  cohort	  had	  low	  IgG	  levels	  (mostly	  due	  to	  low	  IgG1	  levels).	  Two	  of	  
the	   three	   patients	   (III.2,	   IV2)	   are	   currently	   under	   immunoglobulin	   substitution.	   In	  
addition	  in	  one	  patient	  (III.3)	  low	  IgM	  levels	  were	  detected.	  	  
	  
3.2	  Expression	  of	  CTLA-­‐4	  is	  not	  different	  between	  affected	  and	  unaffected	  individuals	  
carrying	  CTLA-­‐4	  R75W.	  	  
Given	   the	   variation	   in	   clinical	   picture,	   an	   outstanding	   question	   is	   the	   extent	   to	  which	  
disease	   manifestation	   relates	   to	   the	   level	   of	   CTLA-­‐4	   deficit	   in	   each	   individual.	  
Accordingly,	   it	   is	   possible	   that	   mutation	   carriers	   who	   do	   not	   develop	   symptoms	   are	  
protected	  by	  higher	  CTLA-­‐4	  expression	  from	  the	  remaining	  wild-­‐type	  allele	  or	  potentially	  
other	  factors	  affecting	  CTLA-­‐4	  expression.	  The	  large	  family	  described	  here	  provided	  an	  
excellent	  opportunity	  to	  test	  this	  hypothesis	  in	  individuals	  with	  the	  same	  mutation	  and	  
we	   therefore	   stained	   blood	   samples	   for	   CTLA-­‐4	   and	   Foxp3	   and	   measured	   CTLA-­‐4	  
expression	   in	   gating	   on	   FoxP3+	   Treg	   (Figure	   2A	   and	   B).	   This	   revealed	   that	   CTLA-­‐4	  
expression	   in	   all	   those	   carrying	   R75W	   mutation	   was	   low	   at	   ~45%	   of	   control	   values.	  
Moreover,	   we	   did	   not	   detect	   differences	   in	   CTLA-­‐4	   expression	   between	   affected	   and	  
unaffected	  individuals	  ex-­‐vivo.	  Indeed,	  the	  absolute	  lowest	  expression	  level	  seen	  was	  in	  
an	   unaffected	   individual.	   We	   also	   investigated	   the	   activation	   status	   of	   CD4	   cells	   by	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staining	  for	  CD25	  expression	  (Figure	  2C	  and	  D).	  Rather	  surprisingly	  CD25	  expression	  on	  
Treg	  was	  lower	  than	  controls,	  however	  all	  CTLA-­‐4	  mutation	  carriers	  had	  reduced	  levels	  
irrespective	   of	   disease	   status.	   Moreover	   there	   was	   no	   evidence	   of	   generalised	   CD25	  
upregulation	  in	  Foxp3-­‐ve	  populations.	  	  CTLA-­‐4	  expression	  was	  replicated	  and	  extended	  
in	  a	   second	  series	  of	  experiments	  ~6	  months	   later.	  As	   shown	   in	  Figure	   3A	   and	  B,	  our	  
initial	  observations	  were	  robust	  and	  no	  difference	  in	  the	  level	  of	  CTLA-­‐4	  expression	  was	  
seen	  between	  affected	   individuals	  or	  unaffected	   individuals	  over	   time.	  Similarly,	   there	  
was	   no	   correlation	   between	   CTLA-­‐4	   expression	   levels	   and	   disease	   severity	   (Table1).	  
These	   experiments	   	   brought	   the	   total	   number	   of	   individuals	   studied	   to	   10	   family	  
members	  including	  2	  unaffected	  carriers.	  	  
A	  frequent	  feature	  of	  CTLA-­‐4	  deficient	  patients	  is	  the	  enrichment	  of	  memory	  (CD45RA-­‐	  
ve)	   CD4	   T	   cells,	   which	   accumulate	   possibly	   as	   a	   result	   of	   impaired	   Treg	   function	   and	  
increased	  T	  cell	  stimulation.	  We	  therefore	  compared	  affected	  and	  unaffected	  individuals	  
to	  address	  whether	  high	  numbers	  of	  memory	  T	  cells	  was	  also	  seen	  when	  stratified	  by	  
age.	   	   As	   shown	   in	   Figure	   3C	   both	   affected	   and	   unaffected	   individuals	   showed	   higher	  
levels	   of	   memory	   T	   cells	   compared	   to	   age	   matched	   controls,	   consistent	   with	   the	  
possibility	   that	   CTLA-­‐4	   deficiency	   was	   penetrant	   in	   this	   respect	   in	   both	   affected	   and	  
unaffected	   individuals.	   Taken	   together	   we	   concluded	   that	   all	   individuals	   carrying	   the	  
R75W	  mutation	  had	   impaired	  CTLA-­‐4	  expression	  ex-­‐vivo	  and	   that	   the	   level	  of	   residual	  
CTLA-­‐4	  expression	  was	  not	  different	  in	  individuals	  who	  remain	  unaffected.	  Furthermore,	  
a	  tendency	  towards	  expansions	  of	  CD4	  memory	  T	  cells	  was	  also	  noted	  in	  both	  affected	  
and	  unaffected	  individuals	  as	  was	  lower	  CD25	  expression	  on	  Treg.	  	  
	  
3.3	  Modest	  Treg	  expansions	  are	  seen	  in	  individuals	  with	  R75W	  mutation.	  	  	  
Previously	   we	   have	   observed	   that	   some	   individuals	   with	   CTLA-­‐4	   mutations	   have	  
expanded	   Treg	   numbers	   [12,	   22].	   However,	   the	   extent	   to	  which	   this	   occurs	   between	  
different	  mutations	  and	  whether	  increased	  Treg	  numbers	  can	  compensate	  in	  unaffected	  
individuals	   is	   not	   clear.	   We	   therefore	   investigated	   whether	   Treg	   percentage	   was	  
different	   between	   affected	   and	   unaffected	   individuals.	   Staining	   for	   Foxp3	   in	   the	   10	  
individuals	  with	  R75W	  mutations	  ex	  vivo	  did	  not	  reveal	  a	  clear	  expansion	  of	  Treg	  relative	  
to	   controls	   in	   the	   resting	   state	   ex	   vivo	   (Figure	   4A).	   However,	   in	   addition,	   we	   also	  
performed	  a	  brief	  stimulation	  (16h)	  with	  CD3/CD28	  antibody-­‐coated	  beads.This	  allows	  
an	   additional	   estimate	   of	   Treg	   numbers	   to	   be	   made,	   as	   stimulation	   improves	   FoxP3	  
staining	  without	  inducing	  proliferation	  at	  this	  time	  point	  [22].	  This	  provided	  a	  suggestion	  
of	   increased	   Treg	   percentages	   in	   both	   affected	   and	   unaffected	   individuals	   (Figure	   4A	  
and	   B).	   However,	   these	   data	   did	   not	   suggest	   that	   compensatory	   expansions	   of	   Treg	  
could	  account	  for	  differences	  in	  disease	  manifestation	  in	  this	  family.	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3.4	  CTLA-­‐4	  upregulation	   in	  response	  to	  T	  cell	   stimulation	   is	  similar	  between	  controls	  
and	  R75W	  mutation	  carriers.	  
Since	   CTLA-­‐4	   expression	   is	   strongly	   upregulated	   upon	   T	   cell	   stimulation,	   we	   also	  
investigated	   whether	   CTLA-­‐4	   expression	   patterns	   were	   different	   between	   individuals	  
following	   activation.	   We	   therefore	   stimulated	   T	   cells	   using	   anti-­‐CD3/CD28	   antibody	  
coated	  beads.	   Importantly,	   stimulation	  with	  beads	   is	  not	  affected	  by	  CTLA-­‐4	   itself	  and	  
therefore	   provides	   an	   equivalent	   stimulus	   in	   all	   mutation	   carriers	   and	   controls.	   The	  
results	   of	   this	   stimulation	   assay	   (Figure	   4B)	   revealed	   robust	   upregulation	   of	   CTLA-­‐4	  
(compared	  with	   unstimulated	   cells	   shown	   in	   Figure	   2A)	   in	   both	   Foxp3+	   and	   Foxp3-­‐	   T	  
cells,	  suggesting	  no	  defects	  in	  response	  to	  stimulation.	  Moreover	  upregulation	  of	  CTLA-­‐4	  
was	   similar	   in	   all	   individuals	   with	   CTLA-­‐4	   mutations.	   In	   all	   cases	   the	   level	   of	   CTLA-­‐4	  
expression	   in	  mutation	   carriers	   remained	   lower	   than	   in	   control	   individuals	   confirming	  
defective	   expression,	   however,	   no	   difference	   in	   CTLA-­‐4	   induction	   or	   expression	   was	  
apparent	  between	  affected	  and	  unaffected	  individuals	  (Figure	  4C).	  Taken	  together	  these	  
data	   indicated	   that	   differences	   in	   expression	   of	   CTLA-­‐4	   under	   either	   resting	   or	  
stimulated	  conditions	  did	  not	  differentiate	  between	  affected	  and	  unaffected	  mutation	  
carriers.	   Similarly,	   whilst	   the	   percentage	   of	   Foxp3+	   cells	   increased	   in	   response	   to	  
stimulation,	   this	   increase	  again	  did	  not	  differentiate	  between	  affected	  and	  unaffected	  
individuals.	  
	  
3.5	  No	  evidence	  of	  CD4	  T	  cell	  hyper-­‐proliferation	  associated	  with	  CTLA-­‐4	  deficiency.	  
An	   issue	   in	   the	   CTLA-­‐4	   field	   is	   the	   extent	   to	   which	   CTLA-­‐4	   deficiency	   causes	   intrinsic	  
hyper-­‐proliferation	   of	   T	   cells.	   This	   is	   based	   on	   the	   concept	   that	   CTLA-­‐4	   expression	  
intrinsically	   inhibits	   the	   T	   cells	   that	   express	   it:	   that	   is	   CTLA-­‐4	   generates	   an	   inhibitory	  
signal	  [25,	  26].	  However	  there	  is	  now	  strong	  evidence	  for	  alternative	  mechanisms	  [27].	  
To	  provide	   further	  perspective	  on	   this	   issue	  and	   to	   investigate	  whether	  differences	   in	  
the	   response	   of	   conventional	   T	   cells	   to	   stimulation	   might	   correlate	   with	   disease	   we	  
tested	  responses	  of	  CD4+	  T	  cells	  from	  CTLA-­‐4	  deficient	  individuals	  to	  stimulation.	  	  In	  this	  
assay	  we	  deliberately	  used	  the	  natural	  CTLA-­‐4-­‐biased	  ligand,	  CD80	  in	  combination	  with	  
a	  TCR	  stimulus	  (anti-­‐CD3)	  to	  stimulate	  proliferation	  [24],	  since	  this	  should	  be	  sensitive	  to	  
any	  CTLA-­‐4	  effects.	  As	   shown	   in	  Figure	   5A	  CD4	  T	   cells	   from	  blood	  ex	   vivo	   showed	  no	  
obvious	  signs	  of	  hyperproliferation	  as	  measured	  by	  Ki67	  analysis	  and	   in	  addition	  there	  
was	  no	  difference	  between	  CTLA-­‐4	  mutation	  and	  healthy	  controls.	  Following	  stimulation	  
(Figure	   5B),	   	   T	   cell	   proliferation	   was	   very	   similar	   in	   all	   individuals	   tested.	   Neither	  
comparison	  between	  healthy	  controls	  and	  mutation	  carriers,	  nor	  between	  affected	  and	  
unaffected	   mutation	   carriers	   provided	   any	   evidence	   of	   hyper-­‐proliferation	   in	   T	   cells	  
CTLA-­‐4	  deficient	   individuals	  (Figure	  5C).	  Thus,	  conventional	  CD4+	  T	  cells	  from	  clinically	  
affected	  individuals	  were	  not	  overtly	  hyperproliferative	  ex	  vivo,	  nor	  more	  responsive	  to	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stimulation	   using	   CD28/CTLA-­‐4	   ligands.	  Moreover,	   there	   was	   no	   correlation	   between	  





CTLA-­‐4	   is	   a	   critical	   regulator	   of	   immune	   tolerance	   and	   loss	   of	   expression	   in	   animal	  
models	   is	   fatal	   shortly	   after	   birth	   due	   to	   extensive	   lymphoproliferation	   and	  
autoimmunity[9].	   The	   severity	   of	   this	   phenotype	   in	   animals,	   likely	   explains	   why	   only	  
individuals	   with	   heterozygous	   mutations	   in	   CTLA-­‐4	   have	   been	   reported	   in	   humans.	  
Whilst	   there	   are	   clear	   parallels	   between	   animal	  models	   of	   CTLA-­‐4	   deficiency	   and	   the	  
human	  disorder,	  heterozygous	  individuals	  provide	  an	  opportunity	  to	  further	  understand	  
the	  details	  of	  CTLA-­‐4	  biology	  in	  humans.	  	  
Similar	   to	   other	   CTLA-­‐4	   mutations,	   the	   clinical	   phenotype	   observed	   within	   this	   large	  
family	  with	  R75W	  mutation	  was	  found	  to	  be	  highly	  variable	  and	  confirms	  the	  previously	  
reported	  broad	  spectrum	  of	  clinical	  manifestations	  ranging	  from	  asymptomatic	  carriers	  
to	   severely	   affected	   patients	   [11,	   12].	   Similarly,	   to	   the	   earlier	   reports	   we	   observed	  
multiple	   organ	   involvement	   and	   patients	   showed	   raised	   infection	   susceptibility	   with	  
mainly	   common	  pathogens	  affecting	   the	   respiratory	   tract.	   In	  addition,	   two	  patients	   in	  
this	   family	   had	   a	   history	   of	   recurrent	   salmonellosis	   and	   poliomyelitis;	   not	   previously	  
associated	  with	  CTLA-­‐4	  deficiency.	   Furthermore,	  we	   report	   here	   for	   the	   first	   time	   the	  
occurrence	   of	   post-­‐infectious	   complications	   (post-­‐streptococcal	   nephritis)	   in	   two	  
patients.	  	  
As	   previously	   described	   in	   patients	   with	   CTLA-­‐4	   mutations,	   several	   of	   our	   patients	  
showed	   recurrent	   diarrhea/enteropathy.	   However,	   none	   of	   them	   suffered	   from	  
extensive	   weight	   loss	   or	   required	   specific	   therapy	   other	   then	   gluten-­‐free	   diet	   or	  
avoiding	  lactose	  ingestion.	  Lymphoproliferation	  (>	  6months	  of	  non-­‐malignant/infectious	  
lymphadenopathy	   or	   splenomegaly)	   was	   found	   in	   20%	   in	   our	   cohort,	   which	   is	   in	   line	  
with	   the	  previous	   reports	   [11,	  12].	  Neurologic	  symptoms	   in	  our	  cohort	  were	  generally	  
unspecific	   and	   defined	   as	   progressive	   memory	   loss.	   However,	   one	   patient	   (V.3)	   was	  
found	   to	   have	   recurrent	   and	   therapy	   refractory	   seizures	   (West	   syndrome).	   As	   brain	  
tissue	  alterations	  have	  been	   reported	   in	  patients	  with	  CTLA-­‐4	  mutations,	   imaging	  was	  
performed	   in	   patient	   V.3	   as	   well	   as	   other	   symptomatic	   patients	   without	   evidence	   of	  
granuloma	  formation.	   	  Autoimmunity	  was	  diagnosed	  in	  several	  patients	  but	  symptoms	  
were	   mild	   and	   did	   not	   require	   long-­‐term	   immunosuppression.	   Interestingly,	   whilst	  
cytopenias	   are	   a	   commonly	   described	   (57%	   each)	   complication	   in	   CTLA-­‐4	  
haploinsufficiency[11,	  12]we	  did	  not	  observe	  this	   in	  our	  patients.	  Furthermore,	  we	  did	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not	   identify	   patients	   with	   granulomatous	   lymphocytic	   interstitial	   lung	   disease	   as	  
previously	  observed[11,	  12].	  
Overall,	  comparing	  with	  the	  previous	  case	  series	  our	  cohort	  all	  of	  whom	  share	  the	  R75W	  
mutation	   showed	   a	   milder	   clinical	   phenotype,	   although	   many	   of	   them	   require	  
continuous	  medical	  care.	  In	  addition,	  one	  patient	  received	  a	  liver	  transplant	  for	  a	  non-­‐
infectious	  unspecified	   liver	  disease	  and	  our	   index	  patient	   is	  currently	  under	  evaluation	  
for	  renal	  transplantation	  due	  to	  a	  chronic	  progressive	  renal	   insufficiency.	  To	  date,	  only	  
patient	   (III.3)	   received	   immunomodulatory	   therapy	   including	   rituximab	   and	   sirolimus	  
(mTor	   inhibitor)	   for	   EBV	   negative	   PTLD.	   Currently,	   none	   of	   the	   patients	   is	   receiving	  
targeted	  therapy	  in	  form	  of	  abatacept,	  mimicking	  CTLA4	  function.	  
Hypogammaglobulinemia	   was	   fairly	   common	   in	   the	   earlier	   cohorts	   (71%	   and	   76%,	  
respectively[11,	  12].	  In	  our	  family	  only	  three	  patients	  (33.3%)	  had	  low	  IgG	  levels	  and	  two	  
of	  them	  are	  receiving	   IVIG	  substitution	  therapy.	  Patient	  V.I	  presented	  aged	  16	  months	  
with	  recurrent	   infections	  and	   low	  IgG	   levels	   for	  age	  and	  received	  monthly	   intravenous	  
immunoglobulin	  therapy.	  12	  months	  later	  IVIG	  substitution	  therapy	  was	  withdrawn	  and	  
he	  maintained	  stable	  immunoglobulin	  levels	  over	  the	  last	  24	  months.	  	  
	  
CTLA-­‐4	   deficiency	   is	   considered	   to	   be	   autosomal	   dominant	   disorder	   with	   incomplete	  
penetrance[11,	   12,	   28,	   29].	   Accordingly,	   not	   all	   individuals	   carrying	   functionally	  
significant	  mutations	  develop	  disease	  symptoms,	   raising	   the	  question	  of	  what	  dictates	  
disease	   development.	   Whilst	   there	   are	   a	   number	   of	   genetic	   and	   environmental	  
possibilities,	   one	   plausible	   explanation	   is	   that	   individuals	  who	  do	  not	   develop	   disease	  
have	  higher	  residual	  CTLA-­‐4	  from	  the	  remaining	  functional	  allele.	  We	  have	  investigated	  
this	   possibility	   here	   and	   shown	   that	   in	   all	   10	   related	   mutation	   carriers	   studied	   (8	  
affected	   and	   2	   unaffected)	   no	   clear	   difference	   in	   CTLA-­‐4	   expression	   was	   observed.	  
Accordingly,	  all	  individuals	  tested	  who	  carried	  the	  CTLA-­‐4	  mutation	  had	  impaired	  levels	  
of	   CTLA-­‐4	   expression	   strongly	   suggesting	   that	   the	   difference	   between	   affected	   and	  
unaffected	   individuals	   does	   not	   relate	   to	   CTLA-­‐4	   expression	   itself.	   This	   result	  was	   the	  
same	   under	   both	   resting	   and	   stimulated	   conditions,	   largely	   ruling	   out	   compensatory	  
variation	  in	  CTLA-­‐4	  promoters,	  transcription	  factor	  binding	  and	  other	  factors	  that	  could	  
affect	   CTLA-­‐4	   expression	   such	   as	   LRBA[10]	   in	   this	   family.	   Additional	   compensating	  
possibilities	  affecting	  the	  CD28/CTLA-­‐4	  pathway	  could	  include	  weaker	  CD28	  signaling	  in	  
individuals	  who	   fail	   to	  develop	  disease.	   The	   fact	   that	  we	  observed	   similar	   fractions	  of	  
Ki67+	  T	  cells	  in	  response	  to	  a	  CD28-­‐dependent	  stimulus,	  in	  both	  affected	  and	  unaffected	  
individuals	  also	  argues	  against	  this	  possibility.	  Given	  that	  there	  does	  not	  appear	  to	  be	  an	  
obvious	   difference	   in	   either	   the	   CD28	   or	   CTLA-­‐4	   response	   between	   affected	   versus	  
unaffected	  individuals,	  this	  argues	  in	  favour	  of	  alternative	  explanations.	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Given	  the	  nature	  of	  CTLA-­‐4	  biology	  in	  controlling	  a	  system	  of	  T	  cells	  with	  highly	  variable	  
TCRs	   there	   is	   ample	   opportunity	   for	   both	   genetic	   and	   environmental	   variation	   to	  
influence	  disease	  outcome.	  As	  is	  evident	  in	  more	  complex	  autoimmune	  disorders,	  it	  may	  
be	  that	  CTLA-­‐4	  heterozygosity	  itself	  is	  still	  insufficient	  to	  trigger	  disease	  but	  provides	  an	  
increased	   (albeit	   extremely	   high)	   risk	  which	   needs	   additional	   genetic	   variation	   and	   or	  
environmental	   influences	   to	   result	   in	   disease	   expression[30].	   Thus	   the	   difference	  
between	  disease	  development	  may	  depend	  on	  the	  presence	  of	  particular	  self-­‐reactive	  T	  
cell	   clones,	   additional	   genetic	   influences	   affecting	   the	   immune	   system[31],	  
environmental	   stimuli	   such	   as	   infections,	   or	   host	   microbiota[32].	   Interestingly	   it	   has	  
been	   shown	   that	   the	   host	   microbiota	   can	   affect	   response	   to	   anti-­‐CTLA-­‐4	  
immunotherapy,	   which	   creates	   CTLA-­‐4	   deficiency	   with	   accompanying	  
autoimmunity[33].	   Clearly	   such	   factors	   are	   likely	   to	   vary	   considerably	   between	  
individuals	  in	  the	  same	  family	  but	  will	  be	  challenging	  to	  elucidate.	  	  	  	  
	  
Another	   interesting	  observation	   from	  this	   family	   is	   that	  we	  did	  not	  observe	   large	  Treg	  
expansions.	  	  The	  expansion	  of	  Treg	  is	  observed	  in	  CTLA-­‐4	  deficient	  T	  cells	  or	  upon	  CTLA-­‐
4	  blockade	  in	  mice	  and	  is	  dependent	  on	  CD28	  function[20,	  34,	  35].	  Moreover,	  there	  is	  a	  
clear,	   but	   subtle,	   trend	   to	   increased	   Treg	   numbers	   in	   CTLA-­‐4	   heterozygote	   mice[12].	  
Accordingly,	   CTLA-­‐4	   deficiency	   should	   increase	   CD28	   engagement	   by	   their	   shared	  
ligands	  resulting	  in	  increased	  Treg	  numbers.	  The	  data	  here	  demonstrate	  that	  the	  picture	  
in	   humans	   is	   also	   variable	   with	   some	   individuals	   carrying	   CTLA-­‐4	   mutations	   having	  
significant	  Treg	  expansions	  and	  others	  less	  so.	  One	  possibility	  is	  that	  this	  depends	  on	  the	  
nature	  of	  the	  mutation.	  For	  example,	  since	  CTLA-­‐4	  is	  dimeric	  there	  is	  the	  possibility	  for	  
dominant	   interfering	   mutations	   in	   some	   cases.	   The	   R75W	   mutation	   is	   located	   a	  
considerable	  distance	  from	  the	  ligand	  binding	  site[12]	  and	  may	  plausibly	  have	  a	  weaker	  
effect	  than	  other	  CTLA-­‐4	  mutations.	  The	  extent	  of	  overall	  impaired	  CTLA-­‐4	  function	  may	  
then	  be	  reflected	  in	  the	  level	  of	  Treg	  expansion.	  	  
	  
Whilst	   we	   had	   insufficient	  material	   to	   carry	   out	   Treg	   suppression	   assays	   directly,	   we	  
have	  previously	  shown	  that	  Treg	  from	  unaffected	  individuals	  carrying	  CTLA-­‐4	  mutations	  
have	   compromised	   suppressive	   activity[12].	  Moreover,	   the	   level	   of	   CTLA-­‐4	   expression	  
directly	  relates	  to	  its	  ability	  to	  capture	  ligands	  and	  suppress	  T	  cell	  co-­‐stimulation[22,	  24].	  
It	  is	  therefore	  highly	  likely	  that	  Treg	  from	  unaffected	  mutation	  carriers	  will	  have	  defects	  
in	   CTLA-­‐4-­‐dependent	   Treg	   function.	   It	   remains	   to	   be	   determined	   whether	   any	   Treg	  
activities	  independent	  of	  CTLA-­‐4	  differ	  between	  affected	  and	  unaffected	  individuals.	  
	  
We	  also	   addressed	   the	  question	  of	  whether	   proliferation	  of	   CD4	  T	   cells	  was	  different	  
between	  affected	  and	  unaffected	  individuals.	  In	  the	  experiments	  performed	  here	  we	  did	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not	   observe	   any	   difference	   in	   proliferation.	   Importantly	   the	   experiments	   were	  
performed	  using	   a	   natural	   ligand	  CD80,	  which	   engages	  both	  CD28	  and	  CTLA-­‐4.	  As	  we	  
expected,	  no	  clear	  differences	  were	  observed	  between	  control	  T	  cell	  proliferation	  and	  
those	   of	   CTLA-­‐4	   mutation	   carriers	   in	   response	   to	   stimulation.	   These	   results	   are	  
consistent	   with	   the	   observation	   that	   CTLA-­‐4	   deficient	   cells	   are	   not	   themselves	  
intrinsically	   defective	   and	   do	   not	   display	   a	   hyperproliferative	   phenotype[36,	   37].	  
Perhaps	  surprisingly,	  we	  also	  found	  no	  evidence	  that	  conventional	  CD4	  T	  cells	  in	  blood	  
from	  patients	  were	  hyperproliferative	  in	  vivo	  with	  Ki67	  staining	  ex	  vivo	  being	  in	  line	  with	  
healthy	   controls.	   Similarly	   we	   did	   not	   observe	   high	   levels	   of	   CD25	   expression	   on	  
conventional	  cells	  as	  a	  marker	  of	  activation.	  Taken	   together	   this	   suggests	   that	  despite	  
conferring	  susceptibility	  to	  autoimmune	  responses,	  	  a	  ~50%	  loss	  of	  CTLA-­‐4	  function	  does	  
not	  appear	   to	   cause	  widespread	  activation	  of	   conventional	  CD4+	  T	   cells.	  Considerable	  
evidence	  now	  suggests	  that	  lymphoproliferation	  due	  to	  CTLA-­‐4	  deficiency	  in	  vivo	  in	  mice	  
results	   from	   a	   lack	   of	   regulatory	   T	   cell	   function	   and	   not	   due	   to	   an	   intrinsic	  
hyperproliferative	   capacity	   of	   CD4	   T	   cells[34,	   35,	   38].	   Thus	   whilst	   CTLA-­‐4	   can	   clearly	  
influence	   conventional	   T	   cell	   function	   [39,	   40]	   it	   does	   not	   appear	   to	   have	  major	   cell-­‐
intrinsic	   impacts	   on	   T	   cell	   proliferation	   to	   ligand	   stimulation[12,	   24].	   Thus	   in	   terms	  of	  
detecting	  CTLA-­‐4	  defects	  in	  humans	  it	  is	  not	  clear	  that	  CD4	  T	  cell	  proliferation	  assays	  are	  
likely	  to	  be	  informative	  when	  assessing	  CTLA-­‐4	  deficiency.	  In	  contrast,	  assays	  that	  detect	  
CTLA-­‐4	   expression,	   ligand	   binding	   and	   uptake	  may	   be	   a	   more	   reliable	   way	   to	   detect	  
CTLA-­‐4	  defects	  [22].	  
	  
5.	  Conclusion	  
In	  summary,	  we	  have	  investigated	  in	  detail	  some	  of	  the	  key	  immunological	  features	  of	  
CTLA-­‐4	   deficiency	   as	   they	   relate	   to	   Treg	   and	   conventional	   CD4	   T	   cell	   biology	   in	   the	  
largest	  family	  reported	  so	  far	  with	  a	  CTLA-­‐4	  heterozygous	  mutation.	  
We	  were	   unable	   to	   detect	   differences	   in	   CTLA-­‐4	   expression,	   Treg	   expansion	   or	   T	   cell	  
proliferation	  as	  a	  basis	  for	  discriminating	  clinical	  severity.	  Our	  observations	  provide	  new	  
insights	   into	   the	   differences	   between	   affected	   and	   unaffected	   individuals	   and	   in	   this	  
family	   largely	   rule	   out	   other	   compensatory	   changes	   in	   the	   CD28/CTLA-­‐4	   pathway	   as	  
being	  an	  explanation	  for	  the	  prevention	  of	  disease	  development.	  Thus	  whilst	  the	  disease	  
phenotype	   is	   incompletely	   penetrant,	   biological	   changes	   due	   to	   the	   CTLA-­‐4	  mutation	  
itself	  appear	  completely	  penetrant	  at	  the	  cellular	  level,	  suggesting	  that	  variation	  in	  the	  
downstream	  sequelae	  of	  T	  cell	  activation	  are	  likely	  to	  explain	  the	  disease	  outcome.	  
	   	  





Figure	  1.	  Pedigree	  of	  family	  with	  CTLA-­‐4	  R75W	  mutations.	  Females	  are	  shown	  as	  circles	  
and	  males	  as	  squares,	  with	  symptoms	  color	  coded	  as	  shown.	  
	  
Figure	  2.	  CTLA-­‐4	  and	  CD25	  expression	  levels	  are	  not	  different	  between	  asymptomatic	  
and	   symptomatic	  mutation	   carriers.	  A).	  Representative	   flow	  cytometry	  plots	   showing	  
CTLA-­‐4	  expression	  in	  control	  and	  mutation	  carriers.	  Samples	  are	  shown	  from	  individuals	  
with	  differing	  degrees	  of	  severity.	  Percentages	  are	  shown	  in	  quadrants	  and	  MFI	  of	  CTLA-­‐
4	   in	   Foxp3	   expressing	   cells	   is	   shown	   in	   large	   font.	  B).	   CTLA-­‐4	   expression	   in	   CD45RA-­‐
Foxp3+	   Treg	   is	   shown	   relative	   to	   naïve	   Tcon	   (CD4+	   CD45RA+	   Foxp3-­‐).	   Asymptomatic	  
carriers	  are	  shown	  as	  triangles.	  C	  and	  D).	  As	  above	  except	  for	  CD25	  expression.	  
	  
Figure	  3	  The	  CTLA-­‐4	  deficient	  phenotype	  is	  stable	  over	  time.	  A).	  	  Repeat	  samples	  from	  
selected	  individuals	  taken	  approximately	  6	  months	  apart	  are	  shown	  (batch	  1	  vs	  batch	  2).	  
Individual	   samples	  are	   from	   individuals	   identified	   in	  Table	   I.	  B).	  Comparison	  of	  CTLA-­‐4	  
expression	   in	   Foxp3+	   Treg	   between	   batches.	   C).	   Percentage	   memory	   CD4	   (CD45RA-­‐)	  
cells	  in	  age	  adjusted	  patients,	  carriers	  and	  controls.	  
	  
Figure	  4	  Treg	  response	   to	   stimulation	  does	  not	  distinguish	   affected	   from	  unaffected	  
mutation	  carriers.	  A).	  Percentage	  Foxp3+	  cells	  as	  a	  fraction	  of	  CD4	  cells	   in	  resting	  and	  
stimulated	   conditions.	   Cells	   were	   stimulated	   with	   CD3/CD28	   beads	   for	   16h.	   	   B).	  
Representative	  flow	  cytometry	  plots	  showing	  CTLA-­‐4	  expression	  in	  control	  and	  mutation	  
carriers.	   CD4+	   T	   cells	  were	   stimulated	   for	   16h	  with	   CD3/CD28	   antibody	   coated	   beads	  
and	   CTLA-­‐4	   expression	   measured	   Samples	   are	   shown	   from	   individuals	   with	   differing	  
degrees	  of	  severity	  as	  identified	  in	  Table	  I.	  Percentages	  are	  shown	  in	  quadrants	  and	  MFI	  
of	  CTLA-­‐4	  in	  Foxp3	  expressing	  cells	  is	  shown	  in	  large	  font.	  C).	  Relative	  CTLA-­‐4	  expression	  
in	   Foxp3+	   Treg	   is	   shown	   following	   stimulation	   for	   all	   individuals	   tested	   plus	   healthy	  
controls.	  Asymptomatic	  carriers	  are	  shown	  as	  triangles.	  
	  
Figure	   5.	   Proliferative	   responses	   of	   CD4	   T	   cells	   are	   similar	   between	   affected	   and	  
unaffected	  individuals.	  90,000	  CD4	  T	  cells	  were	  stimulated	  with	  0.5	  µg/ml	  anti-­‐CD3	  and	  
72,000	   CD80	   expressing	   transfectants.	   At	   day	   5	   cells	   were	   gated	   on	   CD4+	   cells	   and	  
proliferation	  determined	  by	  staining	  with	  Ki67.	  A).	  Representative	  flow	  cytometry	  plots	  
showing	   Ki67	   expression	   in	   control	   and	   mutation	   carriers	   with	   differing	   degrees	   of	  
severity	   ex	   vivo	   before	   stimulation.	   Percentages	   are	   shown	   in	   quadrants.	   B).	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Representative	   flow	  cytometry	  plots	   showing	  Ki67	  expression	   in	   control	   and	  mutation	  
carriers	   at	   day	   5	   after	   stimulation.	   Percentages	   are	   shown	   in	   quadrants.	   C).	   Ki67	  
expression	   in	   conventional	   CD4	   cells	   shown	   for	   all	   individuals	   tested	   plus	   healthy	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Table 1: Clinical manifestations of CTLA4 c.223C>T mutation carriers 
 
 
* Granuloma annulare, chronic refractary urtikaria, atopic dermatitis; ** III.3 PTLD/B cell 
lymphoma, III.4 mamma carcinoma; GLILD: granulomatous-lymphocytic interstitial lung 
















IV.10 IV.11 V.1 
 
V.3  
Clinical phenotype score: 
Aysymptomatic (A): 0 symptoms 
Mild-moderate (MM): 1-5 symptoms 


































Age at investigations (yrs), gender (F/M) 63, F 55, M 65, F 53, F 64, F 68, M 34, F 40, F 33, M 42, M 46, M 38, M 40, M 3, M 10, M  
Psoriasis / other skin disease *                60,0 
Diarrhea / enteropathy                53,3 
Dyslipidemia                53,3 
Recurrent arthralgia                26,7 
Global neurodevelopmental 
delay/Progressive memory loss 
               26,7 
Recurrent respiratory tract infections                20,0 
Recurrent salmonella infection                20,0 
Splenomegaly                20,0 
Liver disease                20,0 
Autoimmune / atrophic gastritis                20,0 
Post-streptococcal nephritis                13,3 
Lymphadenopathy                13,3 
Malignancy **                13,3 
Gastrointestinal dysplasia (adenoma)                13,3 
Poliomyelitis infection                13,3 
Recurrent cutaneous papilloma                6,7 
AI thyroiditis                6,7 
Seizures                6,7 
Growth retardation                6,7 
AI arthritis                6,7 
Recurrent vaginal candidiasis                 6,7 
GLILD                0,0 
AI hemolytic anemia                0,0 
AI thrombocytopenia                0,0 
Present or documented Not reported Not applicable 
 
